Mitchell H. Gold, MD
Dr. Mitchell H. Gold currently serves as executive chairman of Dendreon Corporation's Board of Directors.
Previously, he served as president and chief executive officer of Dendreon since 2003, as well as vice president of business development and as chief business officer when he joined Dendreon in 2001.
In April 2010 ? after more than 15 years of research and development, 15 clinical trials, and more than $1 billion raised ? Dendreon
received approval from the FDA
for the world's first autologous cellular immunotherapy, PROVENGE? (sipuleucel-T).
grew the company from having a market capitalization of $40 million to one of nearly $2 billion, establishing Dendreon
as one of the largest biotech companies in the world.
Prior to joining Dendreon, Dr. Gold previously served as vice president of business development and vice president of sales and marketing for Data Critical Corporation, a company engaged in wireless transmission of critical healthcare data, now a division of GE Medical.
Dr. Gold was the president, chief executive officer, and a co-founder of Elixis Corporation, a medical information systems company.
Dr. Gold currently serves on the board of the University of Washington/Fred Hutchinson Cancer Research Center Prostate Cancer Institute.
Dr. Gold received his B.S. from the University of Wisconsin-Madison and his M.D. from Rush Medical College in Chicago.
Dr. Gold was a resident physician in the Department of Urology at the University of Washington.